PETALING JAYA: Duopharma Biotech Bhd
is likely to see a recovery in its consumer healthcare (CHC) segment, while sales to the government sector is also expected to increase in 2024.
Original article here
2024-01-26
PETALING JAYA: Duopharma Biotech Bhd is likely to see a recovery in its consumer healthcare (CHC) segment, while sales to the government sector is also expected to increase in 2024.